Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + oxaliplatin with concurrent radiotherapy in unresectable pancreatic cancer and distal cholangiocarcinoma
2004-001126-24Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Dec 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC) and distal cholangiocarcinoma (dCCA), sponsored by Ghent University Hospital. Primary endpoint: Feasibility and tolerance. Started Dec 2005; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)distal cholangiocarcinoma (dCCA)
Beyond the preview
Go deeper on 2004-001126-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001126-24.